Vertex Pharmaceuticals Incorporated Announced The Us Food And Drug Administration (Fda) Approved Kalydeco (Ivacaftor) For Use In Children With Cystic Fibrosis (Cf) Ages 1 Month To Less Than Four Months Old Who Have At Least One Mutation In Their Cystic Fibrosis Transmembrane Conductance Regulator (Cftr) Gene That Is Responsive To Kalydeco Based On Clinical And/Or In Vitro Assay Data.Kalydeco Is Already Approved In The Us And Eu For The Treatment Of Cf In Patients Ages Four Months And Older.
